Skip Navigation


Human Reproduction Update Advance Access originally published online on March 28, 2009
Human Reproduction Update 2009 15(4):463-476; doi:10.1093/humupd/dmp011
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
15/4/463    most recent
dmp011v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ivell, R.
Right arrow Articles by Anand-Ivell, R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ivell, R.
Right arrow Articles by Anand-Ivell, R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Biology of insulin-like factor 3 in human reproduction

Richard Ivell1,2,3 and Ravinder Anand-Ivell1,2

1 School of Molecular and Biomedical Science, Research Centre for Reproductive Health, University of Adelaide, SA 5005, Australia 2 Freemasons Foundation Centre for Men's Health, University of Adelaide, SA 5005, Australia

3 Correspondence address. E-mail: richard.ivell{at}adelaide.edu.au

BACKGROUND: Insulin-like factor 3 (INSL3) is a neohormone that has evolved to address specific mammalian traits, in particular, the first phase of testicular descent towards the scrotum during mid-gestation.

METHODS: A thorough literature search was made in PubMed using the terms INSL3, as well as the older synonyms RLF and Ley-IL.

RESULTS: INSL3 is a major secretory product of the testicular Leydig cells in the fetus and in adult men, and in rodent models, reduction in fetal INSL3 expression is an early marker of the testicular dysgenesis syndrome. In women, it is produced in lower amounts by ovarian theca and luteal cells, and circulating levels are increased in women with polycystic ovarian syndrome. During pregnancy, there is evidence for an interaction regulating the feto-placental unit. The presence of INSL3 in amniocentesis samples taken at 12–14 weeks gestation is absolutely specific for male gender, and levels are predictive of subsequent pre-eclampsia and/or birthweight. INSL3 is also involved in adult traits, such as spermatogenesis and bone metabolism. In adult men, INSL3 is constitutively expressed and secreted into the bloodstream at a constant level, reflecting the number and/or functional capacity of the Leydig cells. In complete contrast, testosterone is highly variable within individuals, is acutely responsive to fluctuations in the hypothalamic–pituitary–gonadal axis and appears to have marginal diagnostic value. INSL3 declines consistently with age in adult men.

CONCLUSIONS: INSL3 promises to become an important new diagnostic tool to characterize those men with late-onset hypogonadism and to add clinical diagnostic value at amniocentesis.

Key words: cryptorchidism / hypogonadism / Leydig cells / feto-placental unit / relaxin-like

Received on January 23, 2009; revised February 24, 2009; accepted on March 1, 2009


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Biol. Reprod.Home page
R. Anand-Ivell, K. Heng, B. Hafen, B. Setchell, and R. Ivell
Dynamics of INSL3 Peptide Expression in the Rodent Testis
Biol Reprod, September 1, 2009; 81(3): 480 - 487.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.